The emerging role of exosome and microvesicle- (EMV-) based cancer therapeutics and immunotherapy by Moore, C. et al.
WestminsterResearch
http://www.westminster.ac.uk/westminsterresearch
 
The emerging role of exosome and microvesicle- (EMV-) based 
cancer therapeutics and immunotherapy
Moore, C., Kosgodage, U., Lange, S. and Inal, J.M.
 
This is the peer reviewed version of the following article: Moore, C., Kosgodage, U., 
Lange, S. and Inal, J.M. 2017. The emerging role of exosome and microvesicle- (EMV-) 
based cancer therapeutics and immunotherapy, International Journal of Cancer. 
Accepted Author Manuscript. doi:10.1002/ijc.30672, which has been published in final 
form at: 
https://dx.doi.org/10.1002/ijc.30672
This article may be used for non-commercial purposes in accordance with Wiley Terms 
and Conditions for Self-Archiving.
The WestminsterResearch online digital archive at the University of Westminster aims to make the 
research output of the University available to a wider audience. Copyright and Moral Rights remain 
with the authors and/or copyright owners.
Whilst further distribution of specific materials from within this archive is forbidden, you may freely 
distribute the URL of WestminsterResearch: ((http://westminsterresearch.wmin.ac.uk/).
In case of abuse or copyright appearing without permission e-mail repository@westminster.ac.uk
 The emerging role of exosome and microvesicle- (EMV-) based cancer therapeutics and 
immunotherapy 
Colin Moore
1
, Uchini Kosgodage
1
, Sigrun Lange
2,3
 and Jameel M. Inal
1 
1
Cellular and Molecular Immunology Research Centre, School of Human Sciences, London 
Metropolitan University, London, U.K. 
2
University College London School of Pharmacy, 29-39 Brunswick Square, London WC1N 
1AX, U.K. 
3
University of Westminster, Dept. of Biomedical Sciences, New Cavendish Street, London, 
U.K. 
 
Correspondence to: Prof. J.M. Inal, Cellular and Molecular Immunology Research Centre, 
School of Human Sciences, London Metropolitan University, 166-220 Holloway Road, 
London, N7 8DB, U.K. E-mail address: j.inal@londonmet.ac.uk 
Novelty and Impact Statement: This Mini-Review brings together the field of exosomes and 
microvesicles (EMVs) as drug delivery vehicles together with the burgeoning area of cancer 
immunotherapy. We highlight the promise of cancer immunotherapies using exosomes and 
RNA lipoplexes as cancer vaccines, critically assess the promising but at times controversial 
results using Mesenchymal stem cell-derived EMVs, discuss the possibility of therapeutic 
removal of EMVs and assess the use of EMVs and exosome-mimetic nanovesicles (NVs) as 
drug delivery vehicles. 
 
Keywords: tumour microenvironment; exosomes and microvesicles (EMVs); 
immunotherapy; EMV-based therapy 
This article has been accepted for publication and undergone full peer review but has not been
through the copyediting, typesetting, pagination and proofreading process which may lead to
differences between this version and the Version of Record. Please cite this article as an
‘Accepted Article’, doi: 10.1002/ijc.30672
This article is protected by copyright. All rights reserved.
3 
 
Abstract 
There is an urgent need to develop new combination therapies beyond existing surgery, radio- and 
chemo-therapy, perhaps initially combining chemotherapy with the targeting specificities of 
immunotherapy. For this, strategies to limit inflammation and immuno-suppression and evasion in 
the tumour microenvironment are also needed. To devise effective new immunotherapies we must 
first understand tumour immunology, including the roles of T cells, macrophages, myeloid 
suppressor cells and of exosomes and microvesicles (EMVs) in promoting angiogenesis, tumour 
growth, drug resistance and metastasis. One promising cancer immunotherapy discussed uses 
cationic liposomes carrying tumour RNA (RNA-lipoplexes) to provoke a strong anti-viral-like 
(cytotoxic CD8
+
) anti-tumour immune response. Mesenchymal stem cell-derived EMVs, with their 
capacity to migrate towards inflammatory areas including solid tumours, have also been used. As 
tumour EMVs clearly exacerbate the tumour microenvironment, another therapy option could 
involve EMV removal. Affinity-based methods to deplete EMVs, including an immuno-depletion, 
antibody-based affinity substrate, are therefore considered. Finally EMV and exosome-mimetic 
nanovesicles (NVs) delivery of siRNA or chemotherapeutic drugs that target tumours using peptide 
ligands for cognate receptors on the tumour cells are discussed. We also touch upon the reversal of 
drug efflux in EMVs from cancer cells which can sensitize cells to chemotherapy. The use of 
immunotherapy in combination with the advent of EMVs provides potent therapies to various 
cancers.  
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Introduction 
For decades chemotherapy was the benchmark of cancer treatment but in recent years our 
understanding of tumourigenesis, angiogenesis, epithelial-mesenchymal transition (EMT), metastasis 
and immune modulation, has brought calls for modern, less toxic approaches with improved 
efficacy. Ideal approaches should not only be tailored to a given cancer but also the individual, 
entering the unprecedented age of personalised medicine
1
.  
A tumour comprises cancer and stromal cells whose interplay has adapted it  to evade immunity, by 
avoiding surveillance mechanisms or direct cell-to-cell inhibition, and also by the release of 
exosomes and microvesicles (EMVs) containing functional signalling elements
2
. Cancer cells can 
manipulate their surroundings, by educating tumour-infiltrating cells, to develop an environment 
heavily in favour of tumour growth. Host cells may include fibroblasts, myeloid-derived stem cells, 
mast cells, neutrophils, CD4
+
, CD8
+
, Treg T cells, natural killer (NK) cells, dendritic cells (DCs) and 
macrophages
3-5
. Together, these cells take on pro-tumour characteristics facilitating 
neovascularisation, matrix remodelling, growth signalling, tumourigenesis and inhibition of several 
key immune checkpoints, aimed to halt tumour formation
6
.  
Emerging immunotherapies look to take advantage of existing anti-tumour immune defences, 
redirecting and amplifying them for more specific tumour targeting
7
. Host immunity is able to 
destroy aberrant cells in a selective manner, the most important effector cells being T cells (CD4
+
 
and CD8
+
), DCs and NK cells. Regular immune patrolling and surveillance allows detection of such 
aberrant cells.  Chronic inflammation is a known risk factor of cancer and to survive cancer cells must 
therefore disarm immunity
8, 9
. To rebalance tumour microenvironments, an arsenal of 
immunotherapies are under investigation, including various therapeutic antibodies, DC-based 
vaccination, microbial vectors, adenovirus transfection and various gene therapies
7
. 
Exosomes and Microvesicles (MVs) or EMVs represent two major classes of cell-derived vesicle. 
Extracellular Vesicles (EVs) is a term that encompasses EMVs and apoptotic bodies. They are 
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produced as part of normal cell homeostasis and functions are heavily dependent on the parental 
cell lineage and state of the cell at the time of their release
10-12
. EMVs’ functions range from waste 
removal, to autocrine, paracrine and long distance cell-to-cell signalling. MVs are implicated in a host 
of functions inducing immunomodulation, thrombosis/coagulation, cell growth/apoptosis
13-16
. EMVs 
carry a multitude of functional signalling molecules, including growth factors, cytokines, genetic 
material and RNA transcripts, complement proteins and immune ligands
17-19
. This review will aim to 
cover our current understanding of EMVs in relation to the tumour-host interaction and their 
potential in novel cancer therapies.  
Biogenesis of exosomes and microvesicles 
Exosomes and MVs have proven difficult to fully differentiate from one another, there being 
significant crossover of functionality and size. However they follow very distinctive pathways of 
biogenesis 
20
. MVs typically 0.1-1 µm are produced by budding from the cell surface. One proposed 
mechanism is via increased Ca
2+
i, as was reported by early complement biologists studying removal 
of membrane attack complex (as reviewed later
21
). Higher concentrations of Ca
2+
i
 
activate the lipid 
bi-layer redistribution enzyme, scramblase
22
, whilst sequestering similar lipid distribution enzymes 
floppase and translocase (also known as flippase), that maintain normal membrane asymmetry in an 
ATP-dependant manner
21, 23
. Furthermore, cytoskeletal degradation associated with calpain and 
gelsolin activation leads to membrane blebbing and eventually microvesiculation. Few markers 
distinguish MVs from other vesicles although phosphatidylserine (PS) is known to be highly 
expressed on MVs due to loss of membrane asymmetry
17
. MVs are therefore of non-endosomal 
origin.  
Exosome biogenesis is generally accepted to initiate with the internalisation of surface lipids and 
receptor-mediated endocytosis to form early endosomes. Invagination of early endosomes, results 
in intraluminal vesicles (ILVs), the endosomes now being referred to as multivesicular bodies or 
endosomes (MVBs/MVEs). The two mechanisms for exosome biogenesis (intraluminal budding) are 
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Endosomal Sorting Complex Required for Transport (ESCRT)-dependent and ESCRT-independent. 
ESCRT-I and -II complexes recruited to the outer endosomal surface mediate invagination of the 
endosomal membrane and ESCRT-III induces fission to release ILVs into the MVB. Protein selection 
that is independent of ESCRT involves ubiquitination, as for MHC class II or Epidermal Growth Factor 
Receptor
24
  or sumoylation as for α-synuclein
25
. Examples of ESCRT-independent MVB biogenesis in 
mammalian cells include MVBs being observed even in the absence of all ESCRT complexes (0, I, II, 
and III)
26, 27
 as well as with mouse oligodendroglial, cells where proteolipid protein was sorted into 
ILVs completely independent of ESCRT machinery, but dependent on the sphingolipid ceramide and 
sphingomyelinase
28
. 
MVBs may then follow a degradative pathway fusing with lysosomes, eventually being recycled. 
Alternatively MVBs may fuse with the plasma membrane, whereupon ILVs are released as exosomes. 
These distinct MVBs, with particular cargo and fates, are both present within a cell
12
. 
 
Isolation and characterisation of exosomes and microvesicles 
The efforts to standardise EMV isolation and characterisation procedures have been ongoing
29
 with 
continued basic research revealing new physical and biological properties. Recent reviews have 
detailed isolation procedures
30
, but to date purity of samples has remained elusive such that unless  
a study specifically demonstrates that samples are formed in MVBs, the vesicle populations used will 
likely carry a mixture of EVs derived both endosomal and non-endosomal origin.  
Studies have commonly used differential centrifugation to isolate EMVs according to size from 
conditioned medium. Larger vesicles, typically MVs, are pelleted at 10,000-20,000 g. A second 
centrifugation step of the resultant supernatant at 100,000 g is then used to isolate exosomes which 
are typically smaller than MVs
30, 31
. However, the upper and lower range of exosome and MV sizes 
cross-over and, to confuse matters further, so do their densities
32
. Furthermore, although exosomes 
Page 6 of 26
John Wiley & Sons, Inc.
International Journal of Cancer
This article is protected by copyright. All rights reserved.
7 
 
are smaller than MVs, (50-100 nm), size may be a problematic means of distinguishing the vesicle 
types, as larger exosomes and smaller MVs
33
 have been reported. Unfortunately differential 
centrifugation also relies on the mass of cargo being carried to pellet the vesicle, such that larger 
vesicles that are quite buoyant may fail to pellet in the 10,000-20,000 g spin, whereas smaller higher 
density vesicles may sediment at this force; the density of EMVs,  currently stands in the range of 
1.1-1.19 g/ml
30
.  
Problems with ultracentrifugation (100,000 g) include extravesicular protein and nucleic acid 
clumping, result in inaccurately high protein measurements and numbers of exosomes. To improve 
purity of EMV pellets and remove contaminating extravesicular aggregates, equilibrating density 
gradients may be employed, sucrose mediums being preferred for EMV isolation
34
. Protein 
aggregates sediment whilst EMVs float upwards (a characteristic of their lipid membranes), 
separation of EMVs containing disparate densities then occurring as each EMV will float upwards 
until the respective forces of their density and buoyancy equilibrate
20
. For isolating EMVs from 
differing biological samples, such as saliva, it may be preferable to use other media, such as 
iodixanol density gradient centrifugation
35
. Saliva is reportedly 5-6 times more viscous than plasma
36
, 
so EMVs and proteins fail to equilibrate in appropriate fractions using sucrose gradient 
centrifugation, despite attempting pre-treatment filtration and sonication methods
35
.  
Other methods for EMV isolation include size exclusion chromatography, immunoaffinity 
purification, polymeric precipitation and microfluidics
37
; commercial kits are also a growing venture. 
Assessment of EMV samples may use a range of techniques including electron microscopy, 
nanoparticle tracking analysis, atomic force microscopy, resistive pulse sensing, dynamic light 
scattering, flow cytometry and Western blotting.  
Future vesicle-based cancer therapies may include the use of RNA lipoplexes, MSC-derived EVs, 
exosome-mimetic vehicles and therapeutic removal of EVs 
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The rest of this review will critically assess the various recent vesicle-based therapies, ranging from 
RNA lipoplex use as a candidate cancer vaccine to the sometimes controversial use of mesenchymal 
stem cell-derived EVs with its various anti-tumour effector mechanisms. We also touch upon 
therapeutic removal of exosomes and MVs where they contribute to disease pathology and assess 
the use of EMVs, and exosome-mimetic nanovesicles as drug delivery vehicles. 
Cancer immunotherapies using RNA lipoplexes as cancer vaccines  
In an exciting novel approach to developing an effective cancer vaccine, nanoparticles (cationic 
liposomes)
38
 carrying tumour RNA, so-called RNA lipoplexes (RNA-LPX) have been used. Such RNA 
lipoplexes were able to stimulate an immune response with anti-viral properties (Fig. 1). Essentially, 
given a slightly negative charge, the RNA-LPX were directed to DC-rich areas in mice (lymphoid 
tissues/spleen) and taken up by macrophages and plasmacytoid DC (both CD11c-expressing). Their 
uptake by macropinocytosis was more effective by pDCs, which released a first wave of IFN-α, which 
helped initial T cell priming. The mature dendritic cells (mDCs) then translated the tumour RNA and 
presented the tumour antigens to T cells. A second wave of IFN-α then fully primed the T cells, 
resulting in a strong and enduring anti-tumour response. Initial intravenous vaccination trials in 
melanoma patients showed activation of CD4 and cytotoxic CD8 T cells, as would be expected in an 
anti-viral response along with IFN-α production. 
Mesenchymal Stem Cell-Derived Extracellular Vesicles in Cancer Therapy  
Mesenchymal stem cells (MSCs) are multipotent precursors of bone marrow stroma with the ability 
to differentiate into phenotypes of the mesenchymal germ layer
39
. Their properties in tissue 
differentiation and immunomodulation places them as potential therapeutic options with regard to 
wound healing and regeneration,
40
 and they are particularly interesting as they locate and migrate 
towards damaged and inflammatory microenvironments, including solid tumours
41, 42
. Their 
targeting nature places them in good stead to deliver therapeutic agents such as therapeutic miRNA, 
IFN-β, oncolytic adenovirus and anti-cancer agents
43-45
. Paracrine signalling seems a key mediator of 
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wound healing and anti-inflammatory processes utilised by MSC populations. As expected, analysis 
of MSC-derived EMV cargo has identified the presence of cytokines, growth factors, chemokines, 
mRNA and miRNA cluster groups
32, 46, 47
, in addition to mitochondria and mtDNA,
48
 expanding the 
repertoire of communicative signalling elements associated with MSC vesicles.  
 
Interestingly, MSCs have opposing activities in vivo and in vitro. The contrasting observations 
reported could be due to cell lines used (both MSC and tumour), heterogeneity of MSCs, timing of 
MSC treatment, choice of in vivo model and method of administering MSC populations
49
. For 
example, intravenous injection of homogenous MSCs reduced tumour burden whilst co-injection 
with tumour cells promoted angiogenesis and growth
50
. Nevertheless, MSCs display multi-functional 
activities, both with pro- and anti-tumour activity within the microenvironment. Supporting tumour 
growth may relate to the tissue remodelling activity MSCs perform at inflammatory sites, causing 
localised immunosuppression whilst harmonising multiple cell types of the stroma and 
endothelium
51
. A cancer’s ability to coerce MSCs into collaboration may be vital for survival in some 
cancers, whilst others may utilise cells of other origins or entirely separate survival strategies for 
theirs, as discussed previously
52-56
.  
 
In the context of the EMVs shed from MSCs, Bruno  et al. in 2013
42
 observed increased cell cycle 
arrest in phase G0-G1 and reduced proliferation of cancer cells (HEPG2 hepatoma, Kaposi sarcoma, 
SKOV-3 ovarian cancer cell lines) following MSC-EMV treatment in vitro. Furthermore, reduced 
tumour burdens were noted with in vivo models after MSC-EMV treatment. Gene expression of cell 
cycle proteins found the negative cell cycle regulators retinoblastoma 1 and retinoblastoma-like 1 
and 2 were heightened, whilst progressive cell cycle proteins cyclin D2 (CCND2) and Cullin-3 (CUL3) 
displayed a 2-fold reduction following a 24h MSC-EMV incubation. In support, MSC exosomes 
reportedly suppressed angiogenesis by reducing VEGF expression in breast cancer cells
32
. Molecular 
analysis by qRT-PCR implicated miR-16 in blocking translation of the VEGF mRNA transcript, 
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subsequent VEGF mRNA expression thereby increasing following transfection with a miR-16 
inhibitor. VEGF silencing with miR-16 was also reported by others
57
. Additionally, marrow stromal 
cell-derived exosomes expressing miR-146b arrested glioma growth
58
. Indeed several miRNA clusters 
are reported to support tumour growth, by acting as tumour suppressors or oncogenes, and which 
are not exclusively released by MSCs
59
 . Anti-tumour effects that MSC-EMVs demonstrate was 
further observed both in in vivo and in vitro models of T24 bladder cancer tumours, using human 
cord blood Wharton’s jelly MSCs (hWJMSC-EMVs). Specifically, hWJMSC-EMVs induced T24 
apoptosis and cell cycle arrest, reportedly by upregulating caspase-3 cleavage whilst suppressing Akt 
phosphorylation pathways (Fig. 2A)
60
. Conditioned Medium derived from human liver stem cells 
(HLSC), expressing MSC phenotypes and several embryonic stem cell markers, have also displayed 
anti-tumour effects in several cell lines
61
. The study further reasons that it is the presence of Lefty A 
in the HLSC-conditioned medium that blocks tumour growth by sequestration of Nodal signalling 
pathways (Fig. 2B). The anti-tumour effects appear to be cell-specific, disrupting cell lines with 
exuberant Nodal pathways, namely HepG2, MCF7, KP6, KS and Jurkat. However, when HepG2 cells 
were treated with MSC-CM, lacking Lefty A, the pro-apoptotic and anti-proliferative effects were 
abrogated and it was even observed that there were modest increments in proliferation compared 
to control; others have also reported MSC-EMVs’ impairment of tumour growth
62, 63
. 
 
Compared to MSC cell studies, MSC-EMVs have also shown heterogeneous effector mechanisms. A 
recent study investigated the relationship between BM-MSCs and multiple myeloma (MM) cells, 
where it was found that BM-MSCs from patients with MM (MM BM-MSCs) are phenotypically 
different from BM-MSCs from healthy donors. MM BM-MSC-EMVs were found to express elevated 
levels of IL-6, CCL-2 and fibronectin, whilst downregulating the tumour suppressor miR-15a, amongst 
other miRNAs. It was proposed that MM BM-MSCs support MM progression and dissemination
64
. 
Similar pro-tumour effects have been observed in a renal carcinoma model using hWJMSC-EMVs. 
After treatment with hWJMSC-EMVs, renal carcinoma cell cycles progressed to S phase and 
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proliferated. In vivo, cyclin D1 was upregulated, which supports a transition from G0/G1 to S phase. 
Additionally, HGF protein and mRNA expression became elevated, with EMVs seemingly involved in 
the delivery and stimulation of ARK and ERK1/2 pathways
65
. Subcutaneous co-injection of MSC or 
MSC-EMVs with human gastric cancer cells, SGC-7901, and human colon cancer cells, SW480, 
increased tumour burden and growth, as measured by proliferating cell nuclear antigen (PCNA) 
positive cells. Interestingly, in vitro proliferation was not seen, nor was there any observed 
difference in cell cycle when comparing controls. However, VEGF and CXCR4 mRNA and protein 
expression was heightened in vitro. Therefore, it is thought that the increased tumour burden found 
in vivo is an indirect consequence of MSC-EMVs promoting an angiogenic programme, favouring 
tumour seeding and growth
66
. 
 
Tumours have been reported to release EMVs capable of coercing MSCs into altering their activity as 
explored by Chowdhury et al.
67
, using prostate cancer PC3 cell-derived exosomes. Following PCa-
exosome treatment, BM-MSCs differentiated into myofibroblasts expressing α-SMA in a dose-
dependent manner, which was thought to be facilitated by exosome-derived TGF-β. The PCa-
exosome treated BM-MSC expressed heightened VEGF, HGF, MMP-1, 3 and 13 and promoted 
angiogenesis of HUVECs, as demonstrated by scratch assay and CD31 labelling. Despite TGF-β being 
vital to myofibroblast propagation, TGF-β treated BM-MSCs expressed little or no α-SMA, VEGF, 
HGF, CD31 or MMPs. The mechanism of differentiation, be it exosomal or soluble cytokine, is a key 
determinant in phenotype expression. A similar study also observed BM-MSC differentiation into 
fibroblasts expressing α-SMA when treated with exosomes derived from the cholangiocarcinoma cell 
line, KMBC. Notable increases in IL-6, PDGF-AA, CX3CL, CXCL-1, CCL-2 and MMP-2 were found in BM-
MSCs, supporting the argument for a positive feedback loop between tumours and stromal cells of 
the microenvironment, enhancing tumour growth and survival
68
.  
  
Therapeutic removal of Exosomes and Microvesicles  
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Tumour microenvironments consist of a variety of mutable cell types which become educated and 
adapted to support the success of the primary tumour. Currently, research is littered with examples 
of tumour-derived EMVs tolerising and modulating their environments, promoting metastasis, 
angiogenesis, immunosuppression and drug resistance
69
. This prompted investigations into EMV 
removal from cancer patient sera, attempting to nullify the exertive forces of tumours on 
surrounding cells and tissues. A study from the late 80s explored the use of an extracorporeal 
hemofiltration system to this effect. Removal of low molecular weight proteins (approximately 
<150kDa) caused tumour shrinkage of 50% or more, for those patients that could be evaluated by a 
repeat biopsy, in 6 of the 16 patient sample
70
. Though EMVs were not identified it is thought, 
according to Marleau et al.,
71
 that whole blood ultrapheresis removed exosomes (which would not 
have been known about at the time) but probably also other EVs, because of the great 
heterogeneity of EVs in circulation, and that this removal may have been responsible for the tumour 
shrinkage observed. Aethlon Medical has developed a haemofiltration system using cartridges 
consisting of a porous hollow fibre passage and an affinity matrix, which fit into continuous renal 
replacement therapy machines. The technology, named Adaptive Dialysis-like Affinity Platform 
Technology (ADAPT
TM
), separates blood components <200nm where target antigens interact with 
immobilised agents of the affinity matrix, such as monoclonal antibody, lectins and aptamers, 
therefore drawing specific components out from the blood
71
. Tullis et al. at Aethlon, used Galanthus 
nivalis agglutinin as an affinity substrate, which recognises high mannose glycoproteins on viral 
envelopes to remove virion particles from hepatitis C virus (HCV) patients.
72
 HCV load was reduced in 
infected patients not receiving anti-viral drugs following three, 4-6 h dialysis treatments per week. 
Additionally, drug efficacy and patient response to ribavirin and pegylated interferon (PEG-IFN) 
therapy was also seen. The use of antibodies as affinity substrates (a type of immuno-depletion) are 
also being investigated
73
, with potential to target tumour-specific and associated antigens 
transported on EMV surfaces. Reportedly, antigens such as HER-2
74
 and CD20
75
 are present on the 
surface of breast cancer and B cell lymphoma-derived EMVs respectively and could be viable targets 
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for therapy. Other examples of immuno-depletion used in a non-clinical setting for exosome removal 
from cell culture supernatants, that could form the basis of adapted methods for a clinical setting 
have included anti-CD45-coupled magnetic bead removal following 100,000 g ultracentrifugation
76
 
or as our group described the removal of anti-CD63
biotin
 complexed to exosomes using Streptavidin 
T1 dynabeads
11
.  
 
Use of Exosomes and Microvesicles (EMVs) and exosome-mimetic nanovesicles (NVs) as drug 
delivery vehicles  
EMVs are attractive  drug delivery vehicles due to their membrane composition and the adhesive 
proteins embedded within them, their role in cell-to-cell communication
10
 and because exogenous 
cargo can be loaded into them to deliver therapeutics to tumour sites. Drug incorporation into EMVs 
has involved expression vectors, incubation of cells with the therapeutic in acidic conditions, 
electroporation,
55
 freeze-thaw cycles, sonication, extrusion, treatment with/without saponin and 
permeabilization
77
. EMVs represent an attractive delivery method of RNA species too, given they are 
homeostatic carriers that can readily fuse with cells
78, 79
.  
A murine model by Alvarez-Erviti et al.
80
, utilised ‘self’ immature Dendritic Cell- (iDC-) exosomes. By 
electroporation at 400V, 150µg of siRNA against GAPDH (ubiquitously expressed) and BACE1 (a 
target in Alzheimer’s disease) could be loaded and retained in exosomes. Lamp2b is widely 
expressed on exosomes and was fused to rabies viral glycoprotein (RVG-exo) and ASSLNIA, a 7 amino 
acid muscle-specific peptide (MSP-exo) to target neurons, microglia and oligodendrocytes (by 
acetylcholine receptor) and muscle cells respectively (Fig. 3A). In vivo, naked GAPDH siRNA induces 
gene knockdown of the spleen, liver and kidney, with little apparent delivery to muscle or neurons. 
However, when siRNA was incorporated with RVG exosomes (RVG-exo), GAPDH gene knockdown in 
the striatum, midbrain and cortex was observed with little effect on the spleen or liver; though 
kidney did display knockdown of the gene it was below the threshold of significance. Furthermore, 
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cortical sections from sacrificed mice confirmed that BACE1 siRNA delivered via RVG-exo, 
successfully reduced protein expression (62%), mRNA (61%), and β-amyloid 1-42 aggregates (55%). 
The results give reason to be hopeful for future gene and targeted therapies, though it should be 
noted that a report by Kooijmans SA et al.,
81
 called for more effective methods of EMV loading after 
exploring the efficiency of siRNA uptake in EMVs, and finding retention measurements to be 
misleading. The peak of exogenous siRNA uptake was found at approximately 20-25%. However, the 
group found that without EMVs, siRNA retention remained equally detectable by nanoparticle 
tracking analysis (NTA) and confocal microscopy. Metal ions from the electrodes and hydroxide ions 
from the electroporation buffer were thought to induce the precipitation of siRNA forming 
detectable aggregates. EDTA, citric acid buffers and other methods successfully reduced formation 
of aggregates, but unfortunately this was at the expense of EMV siRNA retention resulting in likely 
overestimation of EMV retention of siRNA.  
Of note, electrical discharge through a solution containing macromolecules, such as DNA, RNA and 
protein, caused significant molecule aggregation; with siRNA unlikely to be the only macromolecule 
affected by such forces, this may present a difficulty when loading various therapeutics into EMVs 
using electroporation
82
. Furthermore, a paper comparing methodologies of exosomal drug 
incorporation found that sonication, rather than electroporation, yielded greater loading of 
paclitaxel (PTX) into exosomes. Exosomal membrane rigidity decreased upon sonication, allowing 
PTX, with a hydrophobic structure, to incorporate itself between the lipid-bilayer as well as attaching 
itself to the surface
83
. An in vivo model was developed using pulmonary metastatic cells (3LL-M27), a 
drug resistant cell line which highly expresses the MDR1 gene and P-gp. Mice treated with 
macrophage-derived PTX-loaded exosomes, displayed a two and three-fold decrease in tumour 
burden in comparison to taxol (50mg/kg) and exosome only treatments, respectively.  
Recently the potential of exosome-mimetic nanovesicles (NVs), prepared by size extrusion of 
monocytes/macrophages, in the delivery of tumour chemotherapeutics, was explored
84
. The NVs 
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loaded with Doxorubicin (dox), caused, significant cell death of HUVECs pre-treated with TNF-α in 
vitro (Fig. 3B). Remarkably, a pre-incubation with VCAM-1, ICAM-1 and E-selectin inactivating 
antibodies abrogated the cytotoxic activity of dox-NVs. In vivo, ICAM-1 dependence was also 
observed for effective targeting as determined by fluorescence. Dox-NVs accumulated in tumour 
sites due to highly expressed ICAM-1
85
, whilst trypsin treatment of NVs nullified targeting capability, 
by removal of the extracellular domain of LFA-1. Freely administered dox diminished tumour weight 
in a dose-dependent manner and synergistically lowered the total number of white blood cells 
(WBCs). Dox-NVs displayed markedly efficient anti-tumour properties as 10µg of NVs, loaded with 
3µg of dox, achieved the same level of tumour reduction as 60µg of free drug and avoided 
diminishing the WBC count. Given the targeting and efficient nature of NVs, they represent a 
promising future therapy.  
The prognosis of patients suffering with glioblastoma multiforme (GBM) is highly dependent on the 
tumour’s chemoresistance, and is often attributed to the expression of the drug efflux transporter P-
glycoprotein (P-gp)
86
. A promoter of the P-gp gene, namely miR-9, was increased two-fold in GBM 
cell lines resistant to Temozolomide (TMZ).
87
  The study sought to target this mechanism of 
resistance through use of MSC exosomes containing the oligonucleotide anti-miR-9, attempting to 
tolerise GBM cells to TMZ. Resistance was reversed as seen by a 20% reduction in cell viability 
compared to TMZ treatment alone and  this coincided with both cleaved and uncleaved caspase 3 
and the fall of P-gp surface expression.  
In agreement with current literature, our group recently reported prostate cancer cells, PC3, to 
competently efflux docetaxel (DTX) by unloading into MVs, and thus contributing to drug 
resistance
11
. However, using a calpain inhibitor (calpeptin) or siRNA (CAPNS1) microvesiculation 
pathways can be blocked. This resulted in a 20-fold increase in docetaxel sensitivity in vitro (Fig. 3C), 
whilst in vivo 0.1mg/kg of DTX with 10mg/kg of calpeptin resulted in reductions in tumour growth 
equal to those achieved with 10mg/kg of DTX alone. Another group identified paclitaxel (PTX) 
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presence in MVs released from murine MSCs. Interestingly, MSC-EMVs were shown to possess anti-
proliferative activity, DTX loaded MSC-MVs significantly and dose-dependently bolstering this effect 
on the metastatic human pancreatic cell line CFPAC-1
88
. A study by Saari et al.
89
, investigated which 
vesicle population is best suited for carrying drug cargo. Using PCa cells, separate ultra-
centrifugations of 20,000 g and 110,000 g were used to isolate MVs and exosomes respectively. 
Vesicles were loaded with high concentrations of PTX and both elicited cytotoxicity, enhancing the 
effects of the drug. However, at low concentrations of PTX, MVs were comparatively more potent 
mediators of cytotoxicity than exosomes. They further found, when drug free, that both vesicle 
species induced proliferation of autologous PCa cells in a dose-dependent manner.  
Finally in work from Muraca’s group, the differential effects of EMVs derived from MSCs of various 
origins were compared including umbilical cord (UC)-MSCs, bone marrow (BM)-MSCs and adipose 
tissue (AT)-MSCs on U87-MG glioblastoma cells
88
. After treating with 25 x 10
9
 MSC-EMVs for 48 h, 
interestingly UC and BM-MSC-EMVs respectively provoked a 3-fold and 2-fold increase in apoptosis 
(Fig. 3D), compared to controls, whilst AT-MSCs caused insignificant changes in cell viability. Further, 
AT-MSC-EMV treated U87-MG cells proliferated with skewed cell cycles towards S and G2/M phases. 
Comparably, UC- and BM-MSC-EMV treatments reduced proliferation; cells became quiescent with 
larger populations entering a sub-G1 phase. Apoptosis of U87-MG could be enhanced 20%-40% 
using UC-MSC-EMVs by loading the UC-MSC-EMVs with Vincristine (Fig. 3D), showing some potential 
for combination therapy.  
   
Conclusions and future directions 
In this era of promising new cancer immunotherapies, vaccination strategies that prevent cancer are 
the ultimate goal. The use of DC-derived exosomes or ‘dexosomes’ to stimulate effective immunity 
has proved disappointing in clinical trials, but nanoparticle RNA vaccines hold huge promise. 
Importantly an RNA-lipoplex based vaccine overcomes the challenge of delivering vaccine antigens 
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to APCs. DC targeting can now be easily achieved by fine tuning the negative charge of the 
nanoparticles, no specific ligand being needed, and as any tumour antigen is encodable by RNA, this 
approach can potentially have applications in many cancers. Other promising therapies that make 
use of our increasing knowledge of the role of EMVs in the tumour microenvironment include 
immuno-depletion of particular EMVs and the use of MSC-derived EMVs. 
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Figure legends 
Figure 1. Cancer vaccines comprising novel RNA lipoplexes (RNA-LPX) Negatively charged RNA 
lipoplexes (RNA-LPX) carrying tumour RNA are taken up by macropinocytosis into DCs where tumour 
RNA is translated and presented provoking a cytotoxic CD8
+
 T cell response with associated waves of  
immunostimulatory IFN-α. 
Figure 2. Cancer therapy using exosomes and microvesicles (EMVs) from mesenchymal stem cells 
In T24 bladder cancer, mesenchymal stem cell EMVs (blue MVs and white exosomes) induced cell 
cycle arrest and apoptosis by upregulating caspase-3 cleavage and suppressing Akt phosphorylation 
(A). EMVs from human liver stem cells (HLSC) carrying Lefty, blocked Nodal signalling in HepG2 liver 
cells and were pro-apoptotic and anti-proliferative (B). 
Figure 3. Exosomes, Microvesicles and Nanovesicles deliver siRNA in Alzheimer’s therapy and 
mediate drug delivery in cancer therapy  Mouse iDC exosomes expressing a rabies viral glycoprotein 
(RVG) were targeted to neurons (A) where they delivered BACE1 siRNA (a target in Alzheimer’s) 
reducing β-amyloid aggregates by 55%. Monocyte derived exosome-mimetic nanovesicles (NVs) 
were prepared by serial extrusion through filters of decreasing pore sizes (10, 5 and 1 µm). NVs 
loaded with Doxorubicin (dox), targeted tumour sites in mice producing the same tumour reduction 
levels as 20 times the amount of free dox; the targeting was due to NV expressed integrin LFA-1 
(CD11a/CD18) affinity for tumour expressed ligand ICAM-1 (CD54) (B). The knowledge that 
microvesicles (MVs) can help remove chemotherapeutic agents from tumour cells was used to 
diminish MV-based drug efflux from prostate cancer cells pharmacologically, using calpeptin (and 
using CAPNS1 siRNA) both in vitro and in vivo. As a result 100-fold lower concentrations of docetaxel 
could be administered with an equivalent reduction in tumour growth (C). In (D) umbilical cord-
derived mesenchymal stem cell (UC-MSC) EMVs (blue MVs and white exosomes) loaded with 
vincristine (Oncovin®) induced double the levels of apoptosis of malignant glioma-derived, U87-MG, 
to 40%. 
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